Motor neuron disease: current management and future prospects.

N G Simon, W Huynh, S Vucic, K Talbot, M C Kiernan

Journal: Internal medicine journal 2016;45(10):1005-13

PMID: 26429216

Abstract

Motor neuron disease (MND) is characterised by progressive neurological deterioration and coexistence of upper and lower motor neuron signs. Over the past decade, evidence has emerged of unique pathophysiological processes, including glutamate-mediated excitotoxicity, which has resulted in the development of novel diagnostic investigations and uncovered potential therapeutic targets. Advances in genetics, including the recently discovered C9orf72 gene, have radically changed the pathological mindset, from MND being classified as a neuromuscular disease to one that MND forms a continuum with other primary neurodegenerative disorders, including frontotemporal dementia. The present review will highlight the improvements that have occurred in clinical care, in conjunction with recent scientific developments.

© 2015 Royal Australasian College of Physicians.

Address: Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.; Westmead Clinical School, C24 Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.; Division of Clinical Neurology, University of Oxford, Oxford, UK.; Brain and Mind Research Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.